Sandhya Girish

5.5k citations

105 papers · 4.1k indexed · 1 hit paper · h-index 30

Impact in

Oncology top 0.5%
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Cancer Immunotherapy and Biomarkers
Radiology, Nuclear Medicine and Imaging top 0.5%
- Monoclonal and Polyclonal Antibodies Research

Papers in

Oncology 92
- HER2/EGFR in Cancer Research 74
- Peptidase Inhibition and Analysis 16
- Cancer Treatment and Pharmacology 16
- Cancer Immunotherapy and Biomarkers 11
Radiology, Nuclear Medicine and Imaging 59
- Monoclonal and Polyclonal Antibodies Research 58

Co-authors: Ian E. Krop Mark X. Sliwkowski Howard A. Burris Patricia LoRusso Ellie Guardino Shanu Modi Jay Tibbitts Hope S. Rugo
Journals: Journal of Clinical Oncology (15 papers)Cancer Chemotherapy and Pharmacology (14 papers)Cancer Research (11 papers)Clinical and Translational Science (7 papers)Clinical Pharmacokinetics (5 papers)
Partner nations: United States France Switzerland

In The Last Decade

Sandhya Girish

102 papers receiving 3.9k citations

Hit Papers

align trajectories log scale

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy 2010 · 568 citations

Peers

Countries citing papers authored by Sandhya Girish

Since Specialization

Citations

This map shows the geographic impact of Sandhya Girish's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandhya Girish with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandhya Girish more than expected).

Fields of papers citing papers by Sandhya Girish

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandhya Girish. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandhya Girish. The network helps show where Sandhya Girish may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Sandhya Girish, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sandhya Girish Line = papers co-authored together Sandhya Girish links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Exposure–Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple‐Negative Breast Cancer Clinical Pharmacology & Therapeutics ·Abhishek G. Sathe, Paul M. Diderichsen, Zhongting Zhang, See‐Chun Phan, Sandhya Girish, Ahmed A. Othman	2024	5
2	Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors Clinical Pharmacokinetics ·Abhishek G. Sathe, Indrajeet Singh, Cecylyana Cavalcante, Paul M. Diderichsen, Xiaohui Wang, Peter Chang, T. G. Villasenor Jorquera, Віталій Лаврук, Sandhya Girish, Ahmed A. Othman	2024	11
3	Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants Clinical and Translational Science ·Rita Humeniuk, Kavita Juneja, Shuguang Chen, Scott Ellis, M. Tercero-Lozano, Deqing Xiao, Sebastià Jornet, M C Johnston, Santosh Davies, Adam DeZure, Yong‐Quan Li, Anu Osinusi, Helen Winter, Sandhya Girish, Ana Paula Oliveira Giorgetti, Mark J. Dresser	2023	5
4	A study of the pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed pregnant women with HIV AIDS ·Tanya Ilieva, Jason T. Hindman, Marta B. Rękawek-Pachwicewicz, 武行若槻, V E Radzinsky, Deqing Xiao, Anchalee Avihingsanon, Priyanka Arora, Ana Paula Oliveira Giorgetti, Sandhya Girish, Dhananjay Marathe	2023	16
5	Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study Cancer Chemotherapy and Pharmacology ·Bei Wang, Rong Deng, Stefanie Hennig, Tanja Badovinac Črnjević, Ririn Lestari Sri Rahayu, Matts Kågedal, Angelica Quartino, Sandhya Girish, Chunze Li, Whitney P. Kirschbrown	2021	11
6	Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma Cancer Chemotherapy and Pharmacology ·Colby S. Shemesh, Priya Agarwal, Tong Lu, Calvin Lee, Randall Dere, Xiaobin Li, Chunze Li, Jin Y. Jin, Sandhya Girish, Dale Miles, Dan Lü	2020	11
7	Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma Pharmaceutical Research ·Dan Lü, Tong Lu, 森川博司, Leonid Gibiansky, Priya Agarwal, Colby S. Shemesh, Randall Dere, Uzor C. Ogbu, Jamie Hirata, Pascal Chanu, Sandhya Girish, Jin Y. Jin, Chunze Li, Dale Miles	2020	13
8	Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting Cancer Chemotherapy and Pharmacology ·Kari M. Morrissey, Mathilde Marchand, Hina Patel, Rong Zhang, Benjamin Wu, Alina F. Bayramova, Almut Mecke, Sandhya Girish, Jin Y. Jin, Helen Winter, René Bruno	2019	62
9	Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study Cancer Chemotherapy and Pharmacology ·Whitney P. Kirschbrown, Matts Kågedal, Bei Wang, Lars Lindbom, Adam Knott, Debbie Carvajal Te, Sharareh Monemi, Ihsan Nijem, Sandhya Girish, М. М. Эверстов, Debora Fumagalli, Robin McConnell, Guy Jérusalem, Chris Twelves, José Baselga, Gϋnter von Minckwitz, José Bines, Amit Garg	2019	9
10	A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics Clinical Cancer Research ·Laurent Claret, Jin Y. Jin, Charles Ferté, Helen Winter, Sandhya Girish, Mark Stroh, Pei He, Marcus Ballinger, Alan Sandler, Amita Joshi, Achim Rittmeyer, D. Gandara, Jean‐Charles Soria, René Bruno	2018	53
11	Application of a Novel ‘Make and Test in Parallel’ Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects Pharmaceutical Research ·Sravanthi Cheeti, Hao Hou, Eric Nelson, Jingwen Liang, Buyun Chen, Roland Morley, Mary Gates, Luna Musib, Sandhya Girish, Srikumar Sahasranaman, Lichuan Liu	2018	6
12	Population pharmacokinetics and exposure–response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2‐targeted regimens British Journal of Clinical Pharmacology ·Fernanda Eduardo Olea do Rio Muniz, Angelica Quartino, Jenny Dahlstrand, Matthew Riggs, Jonathan French, Xin Wang, Shweta Vadhavkar, Melanie C. Smitt, Silke Hoersch, Alexander Strasak, Jin Y. Jin, Sandhya Girish, Chunze Li	2017	17
13	Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats Drug Metabolism Letters ·Ben‐Quan Shen, Daniela Bumbaca, Ramina Sebi Nelson, Ola M. Saad, Jay Tibbitts, S. Cyrus Khojasteh, Sandhya Girish	2015	17
14	Physiologically Based Pharmacokinetic Modeling as a Tool to Predict Drug Interactions for Antibody-Drug Conjugates Clinical Pharmacokinetics ·Yuan Chen, Divya Samineni, Sophie Mukadam, Harvey Wong, Ben‐Quan Shen, Dan Lu, Sandhya Girish, Cornelis E. C. A. Hop, Jin Y. Jin, Chunze Li	2014	32
15	Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer Cancer Chemotherapy and Pharmacology ·Sandhya Girish, Manish Gupta, Bei Wang, Dan Lu, Ian E. Krop, Charles L. Vogel, Howard A. Burris, Patricia LoRusso, Travis Kern, Ola M. Saad, Barbara Tong, Yu-Waye Chu, Scott N. Holden, Amita Joshi	2012	198
16	A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer Cancer Chemotherapy and Pharmacology ·Brendan C. Bender, Mohammed Abul Hasnat, GA Guner, Amita Joshi, Yu‐Waye Chu, Hope S. Rugo, Ian E. Krop, Sandhya Girish, Lena E. Friberg, Manish Gupta	2012	66
17	A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine Journal of Clinical Oncology ·Ian E. Krop, Patricia LoRusso, Kathy D. Miller, Shanu Modi, Denise A. Yardley, Gladys Rodriguez, Ellie Guardino, Michael W. Lu, 江海晖, Sandhya Girish, Lukas C. Amler, Eric P. Winer, Hope S. Rugo	2012	274
18	A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer Cancer ·Muralidhar Beeram, Ian E. Krop, Howard A. Burris, Sandhya Girish, Wei Yu, Michael W. Lu, Scott N. Holden, Shanu Modi	2012	74
19	Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer Current Drug Metabolism ·Dan Lu, Howard A. Burris, Bei Wang, E. Claire Dees, Javier Cortés, Amita Joshi, Manish Gupta, Joo‐Hee Yi, Yu‐Waye Chu, Ted Shih, Liang Fang, Sandhya Girish	2012	30
20	Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer Journal of Clinical Oncology ·Ian E. Krop, Muralidhar Beeram, Shanu Modi, Suzanne F. Jones, Scott N. Holden, Wei Yu, Sandhya Girish, Jay Tibbitts, Joo‐Hee Yi, Mark X. Sliwkowski, Fred Jacobson, Stuart Lutzker, Howard A. Burris	2010	437

About Sandhya Girish

Sandhya Girish is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Genetics, Immunology and Allergy and Hematology, having authored 105 papers that have together received 4.1k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (74 papers), Monoclonal and Polyclonal Antibodies Research (58 papers), Peptidase Inhibition and Analysis (16 papers), Cancer Treatment and Pharmacology (16 papers), Advanced Breast Cancer Therapies (12 papers), Chronic Lymphocytic Leukemia Research (11 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Lung Cancer Treatments and Mutations (7 papers). The work is most often cited by research in Oncology (3.1k citations), Radiology, Nuclear Medicine and Imaging (2.4k citations), Genetics (305 citations), Immunology (561 citations) and Immunology and Allergy (117 citations). Sandhya Girish has collaborated with scholars based in United States, France and Switzerland. Frequent co-authors include Ian E. Krop, Mark X. Sliwkowski, Howard A. Burris, Patricia LoRusso, Ellie Guardino, Shanu Modi, Jay Tibbitts, Hope S. Rugo, Scott N. Holden and Ola M. Saad. Their work appears in journals such as Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Cancer Research, Clinical and Translational Science and Clinical Pharmacokinetics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact